Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders

This phase Ib trial tests the safety and effectiveness of epcoritamab in treating patients with post-transplant lymphoproliferative disorder (PTLD) that has come back after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Epcoritamab, a bispecific antibody, binds to a protein called CD3, which is found on T cells (a type of white blood cell). It also binds to a protein called CD20, which is found on B cells (another type of white blood cell) and some lymphoma cells. This may help the immune system kill cancer cells. Giving epcoritamab may be safe and

Trial Details

NCT ID
NCT06672705
Phase
PHASE1
Sponsor
Timothy Voorhees
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Biopsy
  • Biospecimen Collection
  • Computed Tomography
  • Epcoritamab
  • Positron Emission Tomography
Locations (sample)
  • St Louis, Missouri, United States|38.62727,-90.19789
  • Columbus, Ohio, United States|39.96118,-82.99879

Key Eligibility Criteria

  • Written informed consent obtained to participate in the study and Health Insurance Portability and Accountability Act (HIPAA) authorization for rel…
  • Age ≥ 18 years at the time of consent.
  • Karnofsky scale ≥ 50% or Eastern Cooperative Oncology Group (ECOG) ≤ 2.
  • Histological evidence of B-cell PTLD (any histologic subtype) following solid organ transplantation; expresses CD20; with or without EBV association.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →